Progenics Pharmaceuticals

Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical company focused on innovative therapeutics for patients suffering from cancer and related conditions.  Progenics' pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 2 testing for treatment of prostate cancer, and preclinical stage novel multiplex phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer.  Progenics has exclusively licensed development and commercialization rights for its first commercial product, RELISTOR®, to Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. holds an exclusive license for the subcutaneous formulation. RELISTOR (methylnaltrexone bromide) Subcutaneous Injection is a first-in-class treatment for opioid-induced constipation approved in more than 50 countries for patients with advanced illness.

NEW YORK, June  16, 2020  (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) (“Progenics”), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, announced that at a special meeting of its stockholders held earlier today, Progenics’ stockholders voted to approve its proposed merger with Lantheus Holdings, Inc. (“Lantheus”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, by adopting the previously announced Amended and Restated Agreement and Plan of Merger, dated as of February 20, 2020 (the “Merger Agreement”), by and among Progenics, Lantheus and Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus (“Merger Sub”), pursuant to which Merger Sub will be merged with and into Progenics (the “merger”), with Progenics surviving the merger as a wholly-owned subsidiary of Lantheus.

Progenics Stockholders Approve Merger with Lantheus

NEW YORK, May 27, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company") (NASDAQ: PGNX) in connection with the proposed acquisition of...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Progenics Pharmaceuticals, Inc.

Progenics Pharmaceuticals' (PGNX) CEO David Mims on Q1 2020 Results - Earnings Call Transcript

Progenics: Ready To Decouple From Lantheus After PyL Data

NEW YORK, Jan.  21, 2020  (GLOBE NEWSWIRE) -- The Board of Directors of Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, issued the following letter to shareholders:

Progenics Pharmaceuticals Provides Update on Reconstituted Board’s Ongoing Strategic Review

Progenics Pharmaceuticals, Inc. PGNX, -1.34% said Monday a late-stage trial of a treatment for prostate cancer met its main goal.

Progenics Pharmaceuticals stock soars 29% on news of positive results in prostate cancer drug trial

-  Met Primary Endpoint With a Correct Localization Rate of 84.8–87.0%, Highlighting Strong Diagnostic Performance  -  Company Expects to Submit an NDA to the FDA in the Second Half of 2020   - Conference Call at 8:00 AM Eastern Time

Progenics Pharmaceuticals Announces Phase 3 CONDOR Trial of PyL™ in Prostate Cancer Achieved Primary Endpoint

NEW YORK, Nov.  21, 2019  (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced its Board of Directors has appointed David W. Mims as interim Chief Executive Officer. Mr. Mims, a member of Progenics’ Board of Directors, will assume the leadership of the executive team while the Board of Directors conducts a search to identify a permanent Chief Executive Officer.

Progenics Pharmaceuticals Appoints David Mims as Interim Chief Executive Officer

NEW YORK, Nov.  08, 2019  (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) (“Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that it has delivered all consents and revocations that it has received to its independent inspector of elections in connection with the previously announced consent solicitation by Velan Capital L.P.’s (“Velan”) seeking to reconstitute the Progenics Board of Directors through the removal of three directors and the election of its five nominees and certain other proposals.

Progenics Pharmaceuticals Announces Delivery of Consents and Revocations to Independent Inspector of Elections

Progenics (PGNX) delivered earnings and revenue surprises of 18.52% and -20.35%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Progenics (PGNX) Reports Q3 Loss, Lags Revenue Estimates

Progenics (PGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Progenics (PGNX) to Report a Decline in Earnings: What to Look Out for

November 17 is the Only Deadline for Velan’s Consent Solicitation

Progenics Urges Shareholders to Reject the Risk and Uncertainty That Would be Caused by Giving Velan’s Nominees Control of the Board

Notifies Shareholders that the S-4 Filing on the Value Maximizing Lantheus Transaction will be Filed with the SEC Before November 17

Progenics Reminds Shareholders that November 17 is the Only Deadline for Velan’s Consent Solicitation

ISS Recognizes that Shareholders Should Have Full Information About the Lantheus Transaction Before Making Significant Decisions About the Company

Progenics Strongly Agrees With ISS Recommendation that Velan Group SHOULD NOT Get Majority Control of the Board of Directors

Flags Velan’s Knowledge of Lantheus Transaction Weeks Before It Was Made Public

Progenics Highlights Additional Serious Concerns About Velan Capital, L.P.

Calls Out Velan’s Pattern of Disregard for Good Corporate Governance and Business Ethics

Progenics Sends Letter to Shareholders

Lantheus Holdings

Micro-cap biotech Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) is advancing strongly following an announcement concerning a buyout deal.

Lantheus To Acquire Progenics Pharma In All-Stock Deal

Board Has Made Numerous Corporate Governance Enhancements Reflecting Feedback From Shareholders

Progenics Confirms Notice of Preliminary Consent Solicitation by Velan Capital, L.P. Despite Repeated Efforts by the Company to Reach a Reasonable Resolution

NEW YORK, Sept.  03, 2019  (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that an abstract highlighting PyLTM (18F-DCFPyL) has been selected for poster presentation at the upcoming International Conference on Immunotherapy Radiotherapy Combinations, which will be held from September 12 - 14, 2019 in New York, NY.

Progenics Pharmaceuticals Announces Presentation at the International Conference on Immunotherapy Radiotherapy Combinations

Progenics recently reported their Q2 earnings with a miss on EPS and a beat on revenue. However, Velan Capital is not impressed and released their assessment of the quarter.

Progenics: Volatility Shaking The Tree After A Rough Q2 Earnings

Progenics Pharmaceuticals, Inc. (PGNX) CEO Mark Baker on Q2 2019 Results - Earnings Call Transcript

Progenics (PGNX) delivered earnings and revenue surprises of -9.52% and 55.72%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Progenics (PGNX) Reports Q2 Loss, Tops Revenue Estimates

CytoDyn is moving their PRO 140 product candidate closer towards an FDA approval in HIV. I recall how I discovered CYDY and my plans for starting a speculative position.

CytoDyn: Uncovering An Opportunity

Progenics Pharmaceuticals, Inc. (PGNX) CEO Mark Baker on Q1 2019 Results - Earnings Call Transcript

Progenics (PGNX) delivered earnings and revenue surprises of 8.33% and 15.39%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

News for Progenics Pharmaceuticals Stock (PGNX)